anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Alzheimer's disease (AD), also known as senile dementia, is the most common neurodegenerative disorder characterized by progressive decline in cognitive function and behavioral impairment. It is estimated that there are approximately 9.83 million AD patients in China, with an average annual treatment cost of about $19,144 per person, accounting for 1.47% of the national gross domestic product, surpassing the global average. This not only severely affects the quality of life for elderly patients but also imposes a heavy economic and caregiving burden on families and society.

Due to the limitations of AD treatment and the irreversibility of its progression, early detection and intervention have become the focus of AD prevention and control efforts. Increasingly, scholars propose shifting the diagnosis and intervention of AD to the preclinical stage, particularly the mild cognitive impairment (MCI) phase and even earlier stages characterized by subjective cognitive decline (SCD). Cognitive leisure activity, as one of the potentially modifiable factors in the preclinical stage of AD, understanding its impact on cognitive function and the neural circuitry regulation mechanisms in this stage is of significant importance. This knowledge can contribute to the development of early targeted intervention measures, preventing or delaying the onset and progression of AD, and promoting healthy aging.
The invention discloses a traditional Chinese medicine for treating rhinitis. The traditional Chinese medicine comprises small centipeda herb, astragalus membranaceus, rhubarb, rhizoma coptidis, radix trichosanthis, barley malt, root of Chinese pulsatilla, magnolia flower and fructus xanthii. The medicine is a combination formula, so that the administration of a patient is performed in three phases according to the medicine composition and the formula, and in different phases, the components are changed as follows: (1) 141 g of rhizoma coptidis, 14 g of astragalus membranaceus, 1 g of rhubarb, 5.3 g of radix trichosanthis, and 14 g of fried barley malt; (2) 3.6 g of magnolia flower, 3.6 g of fructus xanthii and 35 g of root of Chinese pulsatilla; and (3) 21 g of root of Chinese pulsatilla, 15 g of small centipeda herb, 2.2 g of magnolia flower, and 2.2 g of Chinese pulsatilla. The formula is a dose for the patient for 5 days, and 15 days are taken as a course of treatment. The processing method of the medicine comprises the following steps: blending the components for each phase according to the proportion, frying the required components, crushing the components, completely stirring the crushed components, and uniformly packaging the mixture into capsules for future use. The administration method is that in 5 days of each course, the patient takes the medicine after meals every day with warm boiled water. The medicine is contraindicated in pregnancy.
Subjects with body surface area (BSA) disease involvement between 10 and 15% will be included. Subjects will receive either 100 milligrams (mg) GW842470X or placebo in a ratio of 2:1.
PURPOSE:An application drug, obtained by laminating a pressure-sensitive adhesive layer, consisting of a copolymer of a methacrylic acid ester or acrylic acid ester and vinylpyrrolidone, and containing a chemical on one surface of a base material sheet, capable of exhibiting drug effect in a short time after the application thereof, and effective for a long term. CONSTITUTION:An application drug obtained by laminating a pressure-sensitive adhesive layer, consisting of a copolymer of a methacrylic acid ester or acrylic acid ester and vinylpyrrolidone, and containing a chemical, e.g. a nitro based compound such as isosorbide dinitrate or nitroglycerol on a base material sheet, e.g. a flexible sheet impermeable to chemicals such as polyethylene, polypropylene or ethylene-vinyl acetate copolymer. The chemical is percutaneously absorbed in a time as short as about 30min, reaches the effective concentration in blood and then is absorbed constantly for about 24hr thereafter. The application drug is well compatible with the skin. The content of the vinylpyrrolidone is preferably 1-60mol% in the above-mentioned copolymer.
This study will systematically examine the NIOSH recommendations on changes in kidney function when the work-to-rest ratio is fixed at 30 min per hour (the most commonly prescribed work-to-rest ratio), but the rate of metabolic heat production and environmental heat stress differs (Figure 2). As described in Study 1, the appropriate rate of metabolic heat production will be elicited by having participants walk on a treadmill at 3 mph and the grade will be adjusted accordingly.
This is a pilot observational study involving patients enrolled in the Seattle VA Bone Marrow Transplant Unit (BMTU) for treatment of their hematologic malignancy. Measurements of patient fitness, body composition, and inflammatory milieu will be performed at visits before HCT, and 30 days (+/- 10 days) after HCT. For patients that continue to receive care at the Seattle VA, additional visits (not exceeding 6 total) may be requested periodically for up to 2 years after HCT.
In patients with high-immunologic risk, it is recommended that Rapamune be used in combination with cyclosporine and corticosteroids for the first 12 months following transplantation [see Clinical Studies (14.3)]. The safety and efficacy of this combination in high-immunologic risk patients has not been studied beyond the first 12 months. Therefore, after the first 12 months following transplantation, any adjustments to the immunosuppressive regimen should be considered on the basis of the clinical status of the patient.

For patients receiving Rapamune with cyclosporine, Rapamune therapy should be initiated with a loading dose of up to 15 mg on day 1 post-transplantation. Beginning on day 2, an initial maintenance dose of 5 mg/day should be given. A trough level should be obtained between days 5 and 7, and the daily dose of Rapamune should thereafter be adjusted [see Dosage and Administration (2.5)].

The starting dose of cyclosporine should be up to 7 mg/kg/day in divided doses and the dose should subsequently be adjusted to achieve target whole blood trough concentrations [see Dosage and Administration (2.5)]. Prednisone should be administered at a minimum of 5 mg/day.

Antibody induction therapy may be used.
All included citizens receive a questionnaire to estimate risk of disease and risk behavior. Information about lifestyle is collated with existing Electronic Patient Record (EPR) data and the citizen's risk of lifestyle-related disease is estimated based on validated algorithms for risk of type-2 diabetes, cardiovascular disease and COPD (Stratification). All citizens receive an electronic health profile and targeted advice. Citizens at increased risk of disease are offered a preventive program at the GP including an initial health examination and subsequent lifestyle counselling. Citizens with risk behavior are offered lifestyle counselling in the municipality and community health services, if necessary. Citizens diagnosed with a lifestyle related disease are already being treated by the GP, and therefore, like citizens with a healthy lifestyle, they are not offered any further services.
BACKGROUND: Ulcerative colitis (UC) is a chronic, recurrent, non-specific inflammatory disease, and the pathogenesis of the disease remains unclear. Ferroptosis is a form of programmed cell death characterized by the accumulation of iron-dependent lipid peroxides, which are simultaneously closely related to reactive oxygen species (ROS). Although seliciclib is highly effective against immune inflammation, its mechanism on colitis is unclear. This study demonstrated that seliciclib administration partially inhibited ferroptosis, alleviating symptoms and inflammation in experimental colitis.
METHODS: The mouse UC model was induced by 3.0 % dextran sodium sulfate (DSS) for 7 days and treated with seliciclib (10 mg/kg) for 5 days. In the in vitro model, LPS (100 μg/mL) was used for induction and seliciclib (10 μM) was applied for 2 h. Meanwhile, appropriate histopathology, inflammatory response, oxidative stress, and ferroptosis regulators were measured.
RESULTS: This study primarily investigated the role of seliciclib in regulating ferroptosis in UC. Bioinformatics analysis indicated that Dual oxidase 2 (DUOX2) may serve a role involved in the ferroptosis of UC. The experimental findings demonstrated that seliciclib alleviates symptoms and inflammation in DSS-induced UC mice and partially mitigates the occurrence of ferroptosis both in vivo and in vitro, possibly through the modulation of DUOX2.
CONCLUSIONS: Ferroptosis is strongly associated with the development of colitis, and seliciclib plays an essential role in ferroptosis and inflammation in UC. The suppression of ferroptosis in the intestinal epithelium could be a therapeutic approach for UC.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine and veterinary science, more exactly maral, Manchurian deer, reindeer velvet antlers technology for making a biologically active powder. There is offered the method which involves cleaning the raw frozen antlers from mechanical pollution, washing, drying at room temperature and simultaneous defrosting to be crushed to particles of size 100 mcm. The crushed antlers are mixed with water in the ratio 1:5. The mixture is homogenised within 5 minutes, extracted during 4 hours at 90-93C, cooled to 40C, with following enzymatic hydrolysis with added papain of activity 30 thous. units. After hydrolysis completed, hydrolysate is centrifuged and filtered; filtrate is kept for 30 minutes at 70C and dried at 45-50C in vacuum 0.9 atm. ^ EFFECT: invention provides preparing the high-quality biologically active product of raw antlers due to optimised technological process, particularly by intensifying fermentation process, faster drying due to reduced amount of water in hydrolysate with using an enzyme more suitable for industrial processing of velvet antlers. ^ 1 ex, 2 tbl
The researchers propose a randomized controlled trial to evaluate how well an intervention, Planned Care for Obesity \& Risk Reduction (Planned CORR), supports primary care treatment of obesity in adults with at least one cardiovascular risk factor (CVRF). We will assess how well it creates initial and sustained improvements in BMI and metabolic, anthropometric and behavioral outcomes in obese adults, age 25 to 70 who have one or more of the following CVRFs: hypertension, smoking or the metabolic syndrome. Planned CORR integrates intervention components based on behavior change theory with a delivery strategy based on the Chronic Care Model (Wagner et al, 2001; also called the "Planned Care Model") and is designed to incorporate intervention principles used successfully to treat obesity. Planned CORR is intended to be compatible with a variety of primary care settings including those with minimal resources to devote to patient education and where most obese adults receive their usual medical care. Study participants will be 380 women and men, age 25-70 who meet the entry criteria of obesity (Class I \& II; BMI 30-45) plus one or more CVRFs. We anticipate that approximately 40% will be Hispanic and we will recruit an equal number of women and men and have powered the study to do analyses by gender. Planned CORR is a stepped care intervention that begins with computer-assisted assessment and tailored action planning, physician or nurse practitioner counseling, and an intensive "first step" of 4 months of lifestyle modification delivered via monthly in-person sessions and phone calls and weekly web or mail (based on preference) tutorials.CVRFs are managed concurrently according to recognized evidence-based protocols. Successive 4-month steps involve more, the same, or less intensive intervention depending on clinical response. The primary aim is to evaluate the effects at 12 \& 24 months of Planned CORR on BMI when compared to enhanced usual care. Secondary aims will evaluate: CVRF outcomes; physiological, metabolic, behavioral, and psychosocial factors related to obesity and CVRFs; quality of life, depression and cost-effectiveness; and medical care quality, patient, provider \& staff satisfaction, process measures relevant to implementation in primary care. Post study aims are to disseminate the knowledge gained from the intervention through conferences and publications, and to disseminate Planned CORR through proven channels of health care intervention dissemination.
Biomechanical preparation will be done using pediatric rotary file system (Kedo-SG blue file system). D1 and E1 files will be used at 300 rpm and 2.4 N/cm torque.
The present invention discloses a medicine for treating intestinal diseases, which is a Chinese patent medicine prepared from pomegranate rind extract, Chinese pulsatilla root extract, common aucklandia root and berberine hydrochloride as raw materials according to a conventional preparation process. The medicine is prepared according to the miao-medical theory. The medicine adopts common Chinese herbal medicines in folk as the raw materials, so the cost is low. The medicine has the functions of resisting bacteria, relieving inflammation, and astringing to stop diarrhea. The medicine has the characteristics of easy preparation, low cost and favorable curative effect. The medicine can be used for treating dysentery, enteritis, etc.
A self-renewing restricted stem cell population has been identified in developing (embryonic day 13.5) spinal cords that can differentiate into multiple neuronal phenotypes, but cannot differentiate into glial phenotypes.  This neuronal-restricted precursor (NRP) expresses highly polysialated or embryonic neural cell adhesion molecule (E-NCAM) and is morphologically distinct from neuroepithelial stem cells (NEP cells) and spinal glial progenitors derived from embryonic day 10.5 spinal cord. NRP cells self renew over multiple passages in the presence of fibroblast growth factor (FGF) and neurotrophin 3 (NT-3) and express a characteristic subset of neuronal epitopes. When cultured in the presence of RA and the absence of FGF, NRP  cells differentiate into GABAergic, glutaminergic, and cholinergic immunoreactive neurons. NRP cells can also be generated from multipotent NEP  cells cultured from embryonic day 10.5 neural tubes. Clonal analysis shows that E-NCAM immunoreactive NRP cells arise from an NEP progenitor cell that generates other restricted CNS precursors. The NEP-derived E-NCAM  immunoreactive cells undergo self renewal in defined medium and differentiate into multiple neuronal phenotypes in mass and clonal culture. Thus, a direct lineal relationship exists between multipotential NEP cells and more restricted neuronal precursor cells present in vivo at embryonic day 13.5 in the spinal cord. Methods for treating neurological diseases are also disclosed.
The web-based growth mindset intervention, called Project Personality, is delivered entirely via Qualtrics and takes approximately 30 minutes to complete. All intervention activities are self-administered by youth and delivered in a web-based format, including illustrations and audio-recordings of text. Intervention content is designed to maximize relevance for youths experiencing symptoms of depression, including excessive sadness and hopelessness.
The invention relates to a scalper bone chelate complex as well as a preparation method and an application thereof. The chelate complex can be used in the fields of medicine, foods and healthcare products. The invention aims at providing the scalper bone chelate complex which can supplement calcium and is prepared by using scalper bone as the raw material. The chelate complex is obtained by stewing, zymohydrolysis and chelation. The preparation method of the chelate complex is simple and easy and convenient to operate with a short time, realizes low energy consumption and can be prepared with the prior conventional methods without the use of special apparatuses. The chelate complex prepared by the preparation method contains the calcium content of 27.8 percent and the total amino acid content of 20.6 percent. The scalper bone chelate complex has good shape, quality and hydroscopic property and favorable fluidity and mouth taste, and the water content and the ash content of the scalper bone chelate complex both meet the requirements. The scalper bone chelate complex has good stability and can be kept for over 2 years. The scalper bone chelate complex can be used for supplementing wholesome components such as calcium, amino acid, and the like.
Gestational diabetes (GDM) is a condition of impaired insulin resistance which causes increased morbidity for mothers and newborns due to fetal overgrowth. Traditionally, GDM is diagnosed with a glucose tolerance test, and treatment subsequently focuses singularly on glucose management. However, both glucose and triglycerides (TAG) are fuels for fetal overgrowth. The central hypothesis is that the most effective understanding of fetal overgrowth needs to include both carbohydrates and triglycerides. The study will focus recruitment on patients who have GDM and BMI \> 35. The specific aims are 1) Determine the relationship between TAG levels during pregnancy and offspring size, 2) Explore the relationship between TAG levels during pregnancy and adipose tissue accrual (birth weight, body composition and adipose tissue distribution) from birth to six months old, and 3)Examine the relationship between maternal TAG levels and cord c-peptide levels. Mothers are asked to check their serum triglycerides at the time of diagnosis of GDM and at the end of pregnancy. Fingerstick blood measurements of triglycerides are also measured every 2 weeks at prenatal visits. At delivery, cord blood is collected. Infants are examined at 0.5, 3, and 6 months after birth.
24,379. Wetter, J., [Hoffmann-La Roche & Co., F.]. Oct. 23. Alkaloids.-Relates to the extraction of the alkaloids contained in opium in a form suitable for subcutaneous injection. A quantity of opium is macerated with dilute hydrochloric acid for twenty-four hours, and the extraction is repeated. The extracts are added together and carbonate of soda is added which precipitates most of the alkaloids. This precipitate, which also contains resins, is mixed with wood chips or the like, and the alkaloids are extracted with alcohol in a Soxhlet apparatus. To the solution remaining, after treating the acid extract with soda, is added an organic solvent such as ether, chloroform, or benzene, the solution is separated, and hydrochloric acid is added, which relieves the organic solvent of alkaloids, and forms an acid solution. The alcoholic extract is distilled, the alkaloids obtained are dissolved in the acid solution, and this is evaporated to dryness in vacuo, leaving a light yellow crystalline powder soluble in cold water and having a feebly acid reaction.
The invention relates to an application of isopimpinellin in the preparation of antitumor drugs and anticancer reversal agents. The invention aims at the pathological and physiological characteristics of tumors, can change the pathological changes of the tumors, and also can enhance the drug concentration of other chemotherapeutic drugs in the tissues and cells of the tumors in order to realize synergistic attenuation effects of the chemotherapeutic drugs. The invention discloses spectroscopic analysis structure confirmation of highly pure isopimpinellin, a preparation method of isopimpinellin, stability study, acute toxicity studies, a medicinal composition containing isopimpinellin, and a new drug use of the above new natural product. Isopimpinellin with the purity of above 98% is obtained through the steps of extracting Fructus Cnidii with ethanol, carrying out macroporous resin decolorization enrichment, and carrying out resin separation and purification. Researches on the pharmacological activity of isopimpinellin show that isopimpinellin has obvious lung cancer, liver cancer and cervical cancer resistances, and has a leukocytogenic effect on leucocytopenia. Isopimpinellin is expected to be developed into low-toxicity and high-efficiency new drugs and anticancer reversal agents used for preventing and treating natural tumors and having pharmacological efficacies, namely drugs for the auxiliary treatment of the tumors.
This review focuses on the question of metabolic syndrome (MS) being a complex, but essentially monophyletic, galaxy of associated diseases/disorders, or just a syndrome of related but rather independent pathologies. The human nature of MS (its exceptionality in Nature and its close interdependence with human action and evolution) is presented and discussed. The text also describes the close interdependence of its components, with special emphasis on the description of their interrelations (including their syndromic development and recruitment), as well as their consequences upon energy handling and partition. The main theories on MS's origin and development are presented in relation to hepatic steatosis, type 2 diabetes, and obesity, but encompass most of the MS components described so far. The differential effects of sex and its biological consequences are considered under the light of human social needs and evolution, which are also directly related to MS epidemiology, severity, and relations with senescence. The triggering and maintenance factors of MS are discussed, with especial emphasis on inflammation, a complex process affecting different levels of organization and which is a critical element for MS development. Inflammation is also related to the operation of connective tissue (including the adipose organ) and the widely studied and acknowledged influence of diet. The role of diet composition, including the transcendence of the anaplerotic maintenance of the Krebs cycle from dietary amino acid supply (and its timing), is developed in the context of testosterone and β-estradiol control of the insulin-glycaemia hepatic core system of carbohydrate-triacylglycerol energy handling. The high probability of MS acting as a unique complex biological control system (essentially monophyletic) is presented, together with additional perspectives/considerations on the treatment of this 'very' human disease.
Improved β-cell function seems to be essential for better glucose homeostasis after Roux-en-Y gastric bypass but is less studied after sleeve gastrectomy (SG). We evaluated the effects of SG on β-cell function in obese patients with diabetes (DM group) and without (control group) in response to both oral and intravenous glucose stimulation. The DM group demonstrated impaired insulin sensitivity and insulin response to glucose before surgery. The insulin sensitivity index of both groups significantly improved after SG. In addition, the insulin response to glucose (early insulinogenic index in oral glucose tolerance test and acute insulin response to glucose in an intravenous glucose tolerance test) increased in the DM group but decreased in the control group. As a result, β-cell function improved significantly in both groups after SG since the disposition index (DI) increased in both. However, the DI of the DM group was not restored to the level of control group up to 1 year after SG. Our results support that obese patients, with and without diabetes, could benefit from SG in β-cell function. For obese patients at risk for or who have been diagnosed with diabetes, interventions should be recommended early to preserve or restore β-cell function, and SG could be an effective choice. Further studies are needed for long-term effects.
Residents in the deliberate practice group received individualized feedback at the end of the initial assessment case. The staff surgeon supervising the case completed 3 previously validated technical skills assessment forms.